BridgeBio Pharma Share Holder Equity 2018-2024 | BBIO
BridgeBio Pharma share holder equity from 2018 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
- BridgeBio Pharma share holder equity for the quarter ending December 31, 2024 was $-1.458B, a 8.54% increase year-over-year.
- BridgeBio Pharma share holder equity for 2024 was $-1.458B, a 8.54% increase from 2023.
- BridgeBio Pharma share holder equity for 2023 was $-1.343B, a 8.02% increase from 2022.
- BridgeBio Pharma share holder equity for 2022 was $-1.243B, a 43.41% increase from 2021.
BridgeBio Pharma Annual Share Holder Equity
(Millions of US $) |
| 2024 |
$-1,458 |
| 2023 |
$-1,343 |
| 2022 |
$-1,243 |
| 2021 |
$-867 |
| 2020 |
$106 |
| 2019 |
$474 |
| 2018 |
$377 |
| 2017 |
$0 |
BridgeBio Pharma Quarterly Share Holder Equity
(Millions of US $) |
| 2024-12-31 |
$-1,458 |
| 2024-09-30 |
$-1,219 |
| 2024-06-30 |
$-1,082 |
| 2024-03-31 |
$-1,037 |
| 2023-12-31 |
$-1,343 |
| 2023-09-30 |
$-1,195 |
| 2023-06-30 |
$-1,350 |
| 2023-03-31 |
$-1,213 |
| 2022-12-31 |
$-1,243 |
| 2022-09-30 |
$-1,128 |
| 2022-06-30 |
$-1,014 |
| 2022-03-31 |
$-1,041 |
| 2021-12-31 |
$-867 |
| 2021-09-30 |
$-739 |
| 2021-06-30 |
$-457 |
| 2021-03-31 |
$-389 |
| 2020-12-31 |
$106 |
| 2020-09-30 |
$216 |
| 2020-06-30 |
$326 |
| 2020-03-31 |
$449 |
| 2019-12-31 |
$474 |
| 2019-09-30 |
$522 |
| 2019-06-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
|
| 2018-09-30 |
$0 |
| 2017-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.894B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
